Marilyn K Glassberg Csete

Medicine & Life Sciences

1. Idiopathic Pulmonary Fibrosis 100%
2. pirfenidone 50%
3. Lung 33%
4. Endothelin-1 22%
5. Lymphangioleiomyomatosis 22%
6. Interstitial Lung Diseases 21%
7. Lung Diseases 21%
8. Placebos 20%
9. Mesenchymal Stem Cells 19%
10. Estrogens 13%
11. Pulmonary Fibrosis 12%
12. Vital Capacity 12%
13. Registries 12%
14. Fibrosis 12%
15. Therapeutics 11%
16. nintedanib 9%
17. Biomarkers 9%
18. Smooth Muscle Myocytes 9%
19. Safety 8%
20. Stem Cells 8%
21. Cell- and Tissue-Based Therapy 8%
22. Mortality 8%
23. Bleomycin 8%
24. Matrix Metalloproteinases 7%
25. Estrogen Receptors 7%
26. Clinical Trials 7%
27. Matrix Metalloproteinase 2 7%
28. Data Analysis 7%
29. Rheumatoid Arthritis 6%
30. Disease Progression 6%
31. Smooth Muscle 6%
32. Sheep 6%
33. Leydig Cells 5%
34. Endothelial Cells 5%
35. Papillary Thyroid Cancer 5%
36. Estradiol 5%
37. Pregnancy Complications 5%
38. Wound Healing 5%
39. Randomized Controlled Trials 5%
40. Dyspnea 5%
41. Leiomyoma 5%
42. 1,5-bis(3,4-dimethoxyphenyl)tetrahydropyran 5%